Hanmi Pharm signs 3.2 tln-won licensing deal with Roche's Genentech for obesity drug candidate

🇰🇷 Yonhap News (KR) —
Hanmi Pharm signs 3.2 tln-won licensing deal with Roche's Genentech for obesity drug candidate

AI Summary

Hanmi Pharm, a South Korean pharmaceutical company, signed a 3.2 trillion won licensing deal with Roche's Genentech for an obesity drug candidate. This marks a significant deal in the pharmaceutical industry with implications for obesity treatment development.

SEOUL, Aug. 24 (Yonhap) -- Hanmi Pharm. Co., a South Korean pharmaceutical compa...

Markets Deals Health Hanmi Pharm Roche Genentech licensing deal obesity drug pharmaceutical industry

Read original source →